A recent Clatterbridge Cancer Centre article discussed a pioneering clinical trial for a cancer vaccine. It was administered to a UK man at The Clatterbridge Cancer Centre in hopes of stopping the recurrence of his head and neck cancer. The vaccine consisted of a therapy custom-tailored to the patient’s DNA and designed to enhance his own immune system to keep cancer away permanently. The patient’s head and neck cancer first arrived in 2011, and returned four times, requiring taxing treatment, facial surgery, reconstruction and radiotherapy.
First Person in UK Receives Cancer ‘Vaccine’
A new clinical trial will determine if a year of immunotherapy injections will keep a four-time cancer patient free of recurrence.
Feb 24, 2022
Pharmaceutical Innovations Report
Discover the latest breakthrough packaging technologies shaping the pharmaceutical sector. This report dives into cutting-edge innovations, from smart containers that enhance patient safety to eco-friendly materials poised to transform the industry’s sustainability practices. All from PACK EXPO. Learn how forward-thinking strategies are driving efficiency and redefining what’s possible in pharma packaging.
Learn More
FDA warning letters surge - is your team prepared?
New guide reveals expert strategies to prevent regulatory issues and respond effectively to FDA enforcement actions in pharmaceutical and medical device manufacturing.
Read More
